Literature DB >> 26319171

Genetic Discoveries Drive Molecular Analyses and Targeted Therapeutic Options in the Epilepsies.

Ryan S Dhindsa1, David B Goldstein.   

Abstract

Epilepsy is a serious neurological disease with substantial genetic contribution. We have recently made major advances in understanding the genetics and etiology of the epilepsies. However, current antiepileptic drugs are ineffective in nearly one third of patients. Most of these drugs were developed without knowledge of the underlying causes of the epilepsy to be treated; thus, it seems reasonable to assume that further improvements require a deeper understanding of epilepsy pathophysiology. Although once the rate-limiting step, gene discovery is now occurring at an unprecedented rapid rate, especially in the epileptic encephalopathies. However, to place these genetic findings in a biological context and discover treatment options for patients, we must focus on developing an efficient framework for functional evaluation of the mutations that cause epilepsy. In this review, we discuss guidelines for gene discovery, emerging functional assays and models, and novel therapeutics to highlight the developing framework of precision medicine in the epilepsies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26319171     DOI: 10.1007/s11910-015-0587-4

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  92 in total

1.  In vivo dynamic clamp study of I(h) in the mouse inferior colliculus.

Authors:  A P Nagtegaal; J G G Borst
Journal:  J Neurophysiol       Date:  2010-06-10       Impact factor: 2.714

Review 2.  The genetics of neuropsychiatric diseases: looking in and beyond the exome.

Authors:  Erin L Heinzen; Benjamin M Neale; Stephen F Traynelis; Andrew S Allen; David B Goldstein
Journal:  Annu Rev Neurosci       Date:  2015-04-02       Impact factor: 12.449

3.  Missense mutations in the sodium-gated potassium channel gene KCNT1 cause severe autosomal dominant nocturnal frontal lobe epilepsy.

Authors:  Sarah E Heron; Katherine R Smith; Melanie Bahlo; Lino Nobili; Esther Kahana; Laura Licchetta; Karen L Oliver; Aziz Mazarib; Zaid Afawi; Amos Korczyn; Giuseppe Plazzi; Steven Petrou; Samuel F Berkovic; Ingrid E Scheffer; Leanne M Dibbens
Journal:  Nat Genet       Date:  2012-10-21       Impact factor: 38.330

Review 4.  Genetic testing in the epilepsies-developments and dilemmas.

Authors:  Annapurna Poduri; Beth Rosen Sheidley; Sara Shostak; Ruth Ottman
Journal:  Nat Rev Neurol       Date:  2014-04-15       Impact factor: 42.937

5.  Genic intolerance to functional variation and the interpretation of personal genomes.

Authors:  Slavé Petrovski; Quanli Wang; Erin L Heinzen; Andrew S Allen; David B Goldstein
Journal:  PLoS Genet       Date:  2013-08-22       Impact factor: 5.917

6.  Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment.

Authors:  Scott C Baraban; Matthew T Dinday; Gabriela A Hortopan
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

7.  Describing the genetic architecture of epilepsy through heritability analysis.

Authors:  Doug Speed; Terence J O'Brien; Aarno Palotie; Kirill Shkura; Anthony G Marson; David J Balding; Michael R Johnson
Journal:  Brain       Date:  2014-07-26       Impact factor: 13.501

8.  A genome-wide association study and biological pathway analysis of epilepsy prognosis in a prospective cohort of newly treated epilepsy.

Authors:  Doug Speed; Clive Hoggart; Slave Petrovski; Ioanna Tachmazidou; Alison Coffey; Andrea Jorgensen; Hariklia Eleftherohorinou; Maria De Iorio; Marian Todaro; Tisham De; David Smith; Philip E Smith; Margaret Jackson; Paul Cooper; Mark Kellett; Stephen Howell; Mark Newton; Raju Yerra; Meng Tan; Chris French; Markus Reuber; Graeme E Sills; David Chadwick; Munir Pirmohamed; David Bentley; Ingrid Scheffer; Samuel Berkovic; David Balding; Aarno Palotie; Anthony Marson; Terence J O'Brien; Michael R Johnson
Journal:  Hum Mol Genet       Date:  2013-08-19       Impact factor: 6.150

9.  Epileptogenic Q555X SYN1 mutant triggers imbalances in release dynamics and short-term plasticity.

Authors:  Gabriele Lignani; Andrea Raimondi; Enrico Ferrea; Anna Rocchi; Francesco Paonessa; Fabrizia Cesca; Marta Orlando; Tatiana Tkatch; Flavia Valtorta; Patrick Cossette; Pietro Baldelli; Fabio Benfenati
Journal:  Hum Mol Genet       Date:  2013-02-12       Impact factor: 6.150

10.  De novo mutations in epileptic encephalopathies.

Authors:  Andrew S Allen; Samuel F Berkovic; Patrick Cossette; Norman Delanty; Dennis Dlugos; Evan E Eichler; Michael P Epstein; Tracy Glauser; David B Goldstein; Yujun Han; Erin L Heinzen; Yuki Hitomi; Katherine B Howell; Michael R Johnson; Ruben Kuzniecky; Daniel H Lowenstein; Yi-Fan Lu; Maura R Z Madou; Anthony G Marson; Heather C Mefford; Sahar Esmaeeli Nieh; Terence J O'Brien; Ruth Ottman; Slavé Petrovski; Annapurna Poduri; Elizabeth K Ruzzo; Ingrid E Scheffer; Elliott H Sherr; Christopher J Yuskaitis; Bassel Abou-Khalil; Brian K Alldredge; Jocelyn F Bautista; Samuel F Berkovic; Alex Boro; Gregory D Cascino; Damian Consalvo; Patricia Crumrine; Orrin Devinsky; Dennis Dlugos; Michael P Epstein; Miguel Fiol; Nathan B Fountain; Jacqueline French; Daniel Friedman; Eric B Geller; Tracy Glauser; Simon Glynn; Sheryl R Haut; Jean Hayward; Sandra L Helmers; Sucheta Joshi; Andres Kanner; Heidi E Kirsch; Robert C Knowlton; Eric H Kossoff; Rachel Kuperman; Ruben Kuzniecky; Daniel H Lowenstein; Shannon M McGuire; Paul V Motika; Edward J Novotny; Ruth Ottman; Juliann M Paolicchi; Jack M Parent; Kristen Park; Annapurna Poduri; Ingrid E Scheffer; Renée A Shellhaas; Elliott H Sherr; Jerry J Shih; Rani Singh; Joseph Sirven; Michael C Smith; Joseph Sullivan; Liu Lin Thio; Anu Venkat; Eileen P G Vining; Gretchen K Von Allmen; Judith L Weisenberg; Peter Widdess-Walsh; Melodie R Winawer
Journal:  Nature       Date:  2013-08-11       Impact factor: 49.962

View more
  6 in total

1.  The Genetic Control of Stoichiometry Underlying Autism.

Authors:  Robert B Darnell
Journal:  Annu Rev Neurosci       Date:  2020-07-08       Impact factor: 12.449

Review 2.  Genomics-Guided Precise Anti-Epileptic Drug Development.

Authors:  Norman Delanty; Gianpiero Cavalleri
Journal:  Neurochem Res       Date:  2017-06-12       Impact factor: 3.996

Review 3.  Precision medicine for genetic epilepsy on the horizon: Recent advances, present challenges, and suggestions for continued progress.

Authors:  Juliet K Knowles; Ingo Helbig; Cameron S Metcalf; Laura S Lubbers; Lori L Isom; Scott Demarest; Ethan M Goldberg; Alfred L George; Holger Lerche; Sarah Weckhuysen; Vicky Whittemore; Samuel F Berkovic; Daniel H Lowenstein
Journal:  Epilepsia       Date:  2022-07-17       Impact factor: 6.740

Review 4.  Drug development in the era of precision medicine.

Authors:  Sarah A Dugger; Adam Platt; David B Goldstein
Journal:  Nat Rev Drug Discov       Date:  2017-12-08       Impact factor: 84.694

5.  A Transcriptome-Based Drug Discovery Paradigm for Neurodevelopmental Disorders.

Authors:  Ryan S Dhindsa; Anthony W Zoghbi; Daniel K Krizay; Chirag Vasavda; David B Goldstein
Journal:  Ann Neurol       Date:  2020-11-18       Impact factor: 10.422

6.  Calcium imaging and dynamic causal modelling reveal brain-wide changes in effective connectivity and synaptic dynamics during epileptic seizures.

Authors:  Richard E Rosch; Paul R Hunter; Torsten Baldeweg; Karl J Friston; Martin P Meyer
Journal:  PLoS Comput Biol       Date:  2018-08-23       Impact factor: 4.475

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.